文献速递新发突发、热带与寄生虫病

非洲疟疾药物体外/离体药敏试验IC50差异综述

Variance in IC50 in in vitro/ex vivo antimalarial drug susceptibility assays in laboratories across Africa.
PubMed 文献 · J Antimicrob Chemother · 2026-01-01

本综述系统分析了2015至2025年间71篇文献,聚焦撒哈拉以南非洲疟疾流行区实验室间抗疟药IC50检测的差异。其中仅56篇来自西非、中非、东非和南部非洲实验室。对西非和东非离体试验IC50值的F检验显示,双氢青蒿素、氯喹、苯芴醇和氨酚喹的IC50值存在统计学显著差异(P<0.05)。药物配制溶剂、浓度范围、暴露时间及曲线拟合工具等差异可能导致IC50值变异,建议区域统一IC50协议并建立质量评估网络。

要点

  • 西非与东非离体试验中双氢青蒿素、氯喹、苯芴醇和氨酚喹的IC50值存在显著差异。
  • 氯喹总体离体IC50值通常低于已知耐药阈值。
  • 药物配制溶剂、浓度范围、暴露时间及曲线拟合工具等差异可解释IC50变异。

核心结论

  • 撒哈拉以南非洲实验室间抗疟药IC50检测存在显著变异,部分主要抗疟药在西非与东非离体试验中IC50值差异有统计学意义。

研究设计与样本

  • 系统综述纳入2015至2025年间发表的71篇文献,评估撒哈拉以南非洲的IC50,其中仅56篇在西非、中非、东非和南部非洲实验室完成。

主要发现

  • 对西非和东非离体试验IC50值的F检验显示,双氢青蒿素、氯喹、苯芴醇和氨酚喹的IC50值存在统计学显著变异(P<0.05)。
  • 西非与东非几何均值分别为:双氢青蒿素2.46 vs 2.21 nM,氯喹83.15 vs 34.34 nM,苯芴醇10.06 vs 10.47 nM,氨酚喹10.63 vs 17.61 nM。
  • 氯喹总体离体IC50值通常低于已知耐药阈值。
  • 观察到药物配制溶剂、药物浓度范围、药物暴露时间(48或72小时)以及曲线拟合工具和检测方法的差异。

关键数值与推荐

  • 建议区域统一抗疟药疗效监测的IC50协议。
  • 建议建立疟疾IC50实验室区域质量评估网络,以促进数据可靠共享并纳入疟疾消除战略计划。

临床怎么用

  • 解读非洲不同实验室IC50数据时需考虑方法学差异,避免直接比较。
  • 推进区域IC50协议统一和质量评估网络建设,以提高监测数据可靠性。

局限性

  • 仅56篇文献来自西非、中非、东非和南部非洲实验室,区域覆盖有限。
  • 药物配制溶剂、浓度范围、暴露时间及曲线拟合工具等差异可能混杂IC50值比较。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Surveillance of antimalarial drug efficacy is essential for drug policy in the fight against malaria. This includes clinical trials of drug efficacy, molecular marker typing and ex vivo/in vitro drug susceptibility tests such as 50% inhibitory concentration (IC50) assay. The goal of this review was to elaborate on the variance in the IC50 assay across labs in sub-Saharan Africa (sSA) where malaria is endemic. We systematically reviewed 71 articles, published between 2015 and 2025, evaluating IC50 in sSA where only 56 were performed in labs in Western (WA), Central (CA), East (EA) and Southern Africa (SA). The IC50 values of the major antimalarial drugs, including dihydroartemisinin (DHA), lumefantrine (LUM), mefloquine (MFQ), amodiaquine (AMD), chloroquine (CQ), piperaquine (PPQ), artesunate (ATS), artemisinin (ART) and quinine (QN), were reported. An F-test performed on the IC50 values from WA and EA, where ex vivo assays were conducted, revealed a statistically significant variation (P value <0.05) in the IC50 values of some major antimalarials (DHA, CQ, LUM and AMD). The geometric means for DHA, CQ, LUM and AMD in WA versus EA were 2.46 versus 2.21, 83.15 versus 34.34, 10.06 versus 10.47, and 10.63 versus 17.61 nM, respectively. The overall ex vivo IC50 values of CQ were generally below the known resistance thresholds. Differences in drug reconstitution solvents, the range of drug concentrations, period of drug exposure (48 or 72 h), and curve-fitting tools and assay methods were observed. These differences together could account for the variance in IC50 values across sSA. We therefore recommend regional harmonization of the IC50 protocol for antimalarial drug efficacy surveillance and formation of a regional quality assessment network of malaria IC50 labs, as a step towards reliable data sharing and integration into strategic plans for malaria elimination.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Egwu CO, Ajibaye O, Oriero E, et al. Variance in IC50 in in vitro/ex vivo antimalarial drug susceptibility assays in laboratories across Africa. J Antimicrob Chemother. 2026. PMID: 42246925. doi:10.1093/jac/dkag187

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。